President and Chief Executive Officer · Aldeyra Therapeutics, Inc. (ALDX)

Todd Brady

A named executive officer of Aldeyra Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$4,704,179

Salary $700,000Stock awards $0

FY2024: $3,931,645

1st of 3 named executive officers at Aldeyra Therapeutics by FY2025 total.

3 named officers on file for Aldeyra Therapeutics, FY2025

Todd Brady’s pay file — $29

  • 9 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Aldeyra Therapeutics’s whole pay program stands against its peers

  • Aldeyra Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ALDX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Todd Brady’s full pay file as a PDF — free

More than this page: up to 10 years of Todd’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Todd Brady compensation by year

Aldeyra Therapeutics Summary Compensation Table · all 9 fiscal years held
In US dollars, as Aldeyra Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Salary$473,000$506,000$523,000$543,871$547,097$559,357$581,170$591,631$700,000
Bonus$0$0$0$0$0$0$0$0$0
Stock awards$697,711$826,838$2,012,500$945,000$545,908$1,130,000$1,613,950$0$0
Option awards$955,632$1,288,517$1,359,210$621,962$2,050,361$818,523$1,236,598$3,000,817$3,801,379
Non-equity incentive$239,800$253,000$235,350$299,129$300,903$338,410$239,733$325,397$189,000
Pension and deferred compensation$0$0$0$0$0$0$0$0$0
All other$0$0$11,201$11,400$11,400$12,200$13,200$13,800$14,000
Total$2,366,143$2,874,355$4,141,261$2,421,362$3,455,670$2,858,490$3,684,651$3,931,645$4,704,179

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aldeyra Therapeutics, Inc. DEF 14A filed April 27, 2026, accession 0001193125-26-182099, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Aldeyra Therapeutics, Inc. filed document, accession 0001193125-26-182099. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.

$2.4M
$2.9M
$4.1M
$2.4M
$3.5M
$2.9M
$3.7M
$3.9M
$4.7M
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU119,375$618,363—
RSU62,500$323,750—
Option624,152—$6.17
Option563,126—$3.62
Option67,709—$6.76
Option5,209—$4.52

Per the Outstanding Equity Awards at Fiscal Year-End table in Aldeyra Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2025 proxy (filed April 27, 2026)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-03Purchase—250,000$1.671,721,298

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Aldeyra Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Todd Brady · this pagePresident and Chief Executive Officer$4,704,179
Stephen MachathaChief Development Officer$1,452,142
Michael AlfieriPrincipal Financial Officer and Principal Accounting Officer$245,963

Board service

Aldeyra Therapeutics board · FY2023

How this board is paid

Company policy: Aldeyra Therapeutics pays directors a $40,000 cash retainer and $116,000 in Options. As stated in Aldeyra Therapeutics's FY2023 proxy.

Committees

Stock Option

The full Aldeyra Therapeutics compensation record

free company brief

This page is one person within Aldeyra Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aldeyra Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Todd Brady's compensation dossier · One-time report. No refunds.